Thyroid Eye Disease - ClinicalTrials.gov

A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients With Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab

In all cohorts and non-responders in Cohorts 1 and 2, who do not enroll in a second therapy session, the Proptosis responders, as well as others, will begin a 52-week Initial Follow-up Period. Infusion q3W for Proptosis non-responders in Cohorts 1 and 2 who want to start a second treatment course of teprotumab. Participants in any of the three cohorts who are proptosis responders and who have flared during the Initial Follow-up Period will be eligible to receive redress.

Source link: https://clinicaltrials.gov/ct2/show/NCT05002998

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions